Cellular Biomedicine Group, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cellular Biomedicine Group, Inc.
ImmunoACT gets go-ahead in India for its CD19-targeted CAR-T cell therapy, which reported low toxicity and the absence of neurotoxicities in clinical trials. The product will come at a huge price differential compared to on-market therapies, offering new hope to several patients.
J&J chairman and CEO Joaquin Duato shares striking glimpses of his own life journey at a recent summit as he underscores the value of diversity, equity and inclusion. He also discusses the company’s formulae for innovation and the Kenvue spin out.
A new collaboration with Cellular Biomedicine includes a CD19/CD20-directed bispecific CAR-T in Phase I development for B-cell non-Hodgkin lymphomas.
AstraZeneca has been drawn back to drug development innovation in China after accelerating its rate of licensing deals with biotechs in the country over the past few months. Meanwhile, the UK multinational has also been building a network ecosystem together with a Chinese investment bank to take a long-term view in the country, a senior R&D executive told Scrip in an interview.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Agreen Biotech Co. Ltd. China
- CBMG Holdings
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.